Genetic deficiency of human mast cell alpha-tryptase.

BACKGROUND: Human alpha- and beta-tryptases are proteases secreted by mast cells. Beta (but not alpha) tryptases are implicated in asthma. Genes encoding both types of tryptases cluster on chromosome 16p13.3. OBJECTIVE: This study examines the hypothesis, generated from mapping data, that alpha-alleles compete with some beta-alleles at one locus and that an adjacent locus contains beta-alleles exclusively. This hypothesis predicts that beta-alleles outnumber alpha and that some genomes lack alpha genes altogether. METHODS: To test this hypothesis, we developed PCR-based techniques to distinguish alpha from beta genes. We then genotyped genomic DNA from individuals and tryptase-expressing cell lines. RESULTS: In support of our hypothesis, we find that alpha-tryptase deficiency affects 80/274 (29%) of individuals surveyed. The genotype of the alpha-deficient individuals is betabetabetabeta, due to inheritance of four beta genes. The percentage of the population with the mixed genotypes alphaalphabetabeta and alphabetabetabeta is 21% and 50%, respectively. Accounting for all alpha- and beta-alleles at the tandem loci on 16p13.3, overall alpha-allele frequency is only 0.23, with beta-alleles considerably outnumbering alpha as hypothesized. In samples of defined ethnicity, alpha deficiency affects 45% of Caucasians, but a much lower percentage of other backgrounds, including African-Americans and Asians. Examination of cell lines reveals that HMC-1 and U-937 lack alpha-genes; thus, lack of alpha transcripts in these cells is due to absence of alpha-genes rather than beta-selective transcription. By contrast, alpha-transcribing Mono Mac 6 and KU812 cells contain alpha- and beta-genes. CONCLUSIONS: Genetic alpha-tryptase deficiency is common and varies strikingly between ethnic groups. Because beta-tryptases are implicated in allergic disorders, inherited differences in alpha/beta-genotype may affect disease susceptibility, severity and response to tryptase inhibitor therapy.

Prostaglandins, thromboxanes, and leukotrienes in inflammation.

Arachidonic acid undergoes two metabolic pathways in leukocytes. The first, catalysis by prostaglandin cyclo-oxygenase, yields the prostaglandin endoperoxides G2 and H2 and thromboxane A2, which induce rapid irreversible aggregation of human platelets and are potent inductors of smooth muscle contraction. The second pathway, catalysis by lipoxygenase, yields various hydroperoxy acids. In platelets, 12-hydroperoxyeicosatetraenoic acid is the predominant product; in polymorphonuclear leukocytes, 5-hydroperoxyeicosatetraenoic acid is formed. These are primarily reduced to 12-hydroxyeicosatetraenoic acid and 5-hydroxyeicosatetraenoic acid. 5-Hydroperoxyeicosatetraenoic acid may also be dehydrated to leukotriene A4. Enzymatic hydrolysis of leukotriene A4 yield leukotriene B4, a potent mediator of leukocyte function. Prostaglandins, thromboxanes, and some hydroxyeicosatetraenoic acids exert chemotactic effects on polymorphonuclear leukocytes. In this respect, leukotriene B4 is the most active compound derived from arachidonic acid. In vivo, adherence of leukocytes to the endothelium of microvessels near inflammatory areas and the sticking phenomenon of these cells are the initial hallmarks of an inflammatory response. In vitro, these responses seem to correspond with leukocyte aggregation and adherence. Leukotriene A4 may also react to form leukotriene C4 (a natural component of slow-reacting substance of anaphylaxis), leukotriene D4, leukotriene E4, and the 11-trans-isomers. All three leukotrienes are virtually unable to induce chemotaxis, enzyme release, or leukocyte aggregation, but they possess biologic properties previously attributed to slow-reacting substances, such as a potent effect on smooth muscle in the peripheral airway and an ability to markedly increase macromolecular permeability in venules. In addition to prolonging bleeding time and causing gastric ulcers, aspirin and other nonsteroidal anti-inflammatory drugs can trigger or aggravate an asthmatic attack. Aspirin can also trigger or aggravate urticaria, probably as a direct effect of thioether leukotrienes rather than from antibody mediation. Many nonsteroidal anti-inflammatory drugs increase formation of slow-reacting substance-A after challenge with allergen, perhaps by inhibiting cyclo-oxygenase, thereby releasing more arachidonic acid for metabolism by lipoxygenase. Alternatively, certain prostaglandins inhibit liberation of arachidonic acid from phospholipids; inhibiting their formation causes release of more arachidonic acid, which must be metabolized by different lipoxygenase pathways, since the cyclo-oxygenase pathway is closed.

Effects of auranofin on leukotriene production and leukotriene stimulated neutrophil function.

Arachidonic acid is metabolized in neutrophils by lipoxygenase to leukotrienes, which are suggested to play a central role in inflammation. The antirheumatic drug auranofin (4 micrograms/ml) was found not to inhibit neutrophil production of the lipoxygenase products 5-HETE-, 15-HETE and LTB4, in vitro when stimulated with the calcium ionophore A23187. Auranofin, however, modulated neutrophil aggregation, enzyme release and chemotaxis induced by LTB4. The results suggest that auranofin may exert some of its antirheumatic effects through affecting neutrophil responses to leukotrienes.

Effects of leukotrienes and f-Met-Leu-Phe on oxidative metabolism of neutrophils and eosinophils.

We assessed the effects of several leukotrienes and of f-Met-Leu-Phe on oxygen consumption in neutrophils and on the initial burst of chemiluminescence (CL) in both neutrophils and eosinophils. It was found that f-Met-Leu-Phe initiated 2.6 times higher oxygen consumption in neutrophils than did leukotriene B4 (LTB4). f-Met-Leu-Phe also stimulated five to 10 times more CL from both types of granulocytes than LTB4, which was at least five times more potent than its omega-hydroxylated metabolite, 20-OH-LTB4, whereas the corresponding 20-COOH derivative was effective only in eosinophils. The double dioxygenation product 5(S), 12(S)- DHETE caused no CL. Neutrophils from patients with chronic granulomatous disease did not respond with CL to any of the agents. The peak of CL occurred 50 to 60 sec after the addition of fMLP, whereas the LTB4-associated peak occurred after 5 to 6 sec and then rapidly subsided. The treatment of cells with sodium azide to inhibit the myeloperoxidase system did not change the kinetics or the rapid decline of the LTB4-induced CL. The CL response to LTB4 could be inhibited to 85% by 0.5 microgram/ml of superoxide dismutase, to 72% by 200 mg/ml of catalase, and to 50% by 80 microM of mannitol. The corresponding figures for f-Met-Leu-Phe-induced CL were 80, 58, and 16%, suggesting that, although a substantial part of the CL appears to be due to superoxide ion production, other oxygen radicals are involved in luminol-enhanced CL production. Thus, in contrast to some previous reports that leukotrienes do not stimulate an oxidative metabolic response in granulocytes despite their potent activity as chemotactic factors, our studies show that leukotrienes are definite inducers of granulocyte oxidative metabolism.

Leukotriene biosynthesis by polymorphonuclear leukocytes from two patients with chronic granulomatous disease.

Polymorphonuclear leukocytes (PMNL) isolated from two patients with chronic granulomatous disease (CGD) were tested for their ability to metabolize arachidonic acid to lipoxygenase products including 5(S),12(R)-dihydroxy-6,14-cis-8,10-trans-eicosatetraenoic acid (LTB4). Analyses of incubations of these PMNL with arachidonic acid and the calcium ionophore A23187 did not differ from simultaneous controls in the production of LTB4, other 5,12-dihydroxy-eicosatetraenoic acids, or monohydroxy-eicosatetraenoic acids. The clinical diagnosis of CGD was confirmed in both cases by determination of PMNL chemiluminescence. Leukocytes from both patients failed to generate active oxygen species in response to either LTB4 or formyl-methionyl-leucyl-phenylalanine. The observation of arachidonic acid oxidation in the absence of superoxide anion precludes a role for the active oxygen species in this metabolic process. These studies clearly dissociate the ionophore-induced leukocyte respiratory burst from the oxidation of arachidonate to the leukotrienes. In addition, the defect of CGD appears to be unrelated to the ability of PMNL to carry out arachidonate oxygenation.

Effects of leukotriene C4 and prostaglandin E2 on the rat mesentery in vitro and in vivo.

Leukotriene C4 (LTC4) and Prostaglandin E2 (PGE2) have been studied for their effects on the rat mesentery in vitro and in vivo. Their effects on the norepinephrine (NE) induced vasoconstrictions in the above vascular bed have also been investigated. LTC4 (10(-10)M) and PGE2 (2.8 X 10(-7)M) produced no direct effects on the perfusion pressure in the isolated perfused rat mesentery. However, LTC4 (10(-10)M) produced constriction of the arterioles in vivo. PGE2 (2.8 X 10(-7)M) did not produce any direct effect on the microcirculation. Indomethacin, when superfused for 10 min. in a concentration of 7 X 10(-5)M, produced significant arteriolar constriction; this effect was reversed when PGE2 was added to the superfusing media containing indomethacin. LTC4, perfused in a concentration of 10(-10)M, produced a time - dependent inhibitory effect on NE induced vasoconstrictions in vitro whereas PGE2 perfusions (2.8 X 10(-7)M) potentiated the NE responses. This potentiating effect of PGE2 was inhibited by indomethacin. In contrast, the topical application of PGE2 in vivo attenuated NE responses of the mesenteric arterioles.

The local edemogenic effects of leukotriene C4 and prostaglandin E2 in rats.

Leukotriene C4 (LTC4) and prostaglandin E2 (PGE2) have been studied for their effects on vascular permeability in rats. LTC4 and/or PGE2 were dissolved in 0.3% ethanol and were administered subcutaneously (0.1 m1) in the plantar surface of one of the hind paws of different series of rats. The changes in vascular permeability were measured by the radioactive marker (HSA.I125) method. LTC4 administered in dose of 2 X 10(-8) M produced marked increase (77 and 133%) in the vascular permeability (local edemogenic effect). PGE2 administered in a dose of 10(-6) M also produced significant increase (38 and 40%) in the vascular permeability. However, PGE2 in the same dose either administered along with LTC4 or administered at 30 minutes after the injection of LTC4 (2 X 10(-8) M) did not have any potentiating effect on the edemogenic response of LTC4.

Effects of novel lipoxygenase products on migration of eosinophils and neutrophils in vitro.

Since it has been suggested that a lipoxygenase product might be specific chemotactic factor for eosinophils, we assessed the stimulating effects of a variety of lipoxygenase products (LTB4, 20-OH-LTB4, 20-COOH-LTB4 and 5(S)12(S)-DHETE) on both neutrophil and eosinophil migration under agarose. LTB4 was the most potent lipoxygenase cytotaxin for neutrophils as well as eosinophils and its stimulating potential for both cell types was similar. The other leukotrienes stimulated migration of neutrophils less than LTB4, whereas eosinophils did not respond. Thus, the previous suggestion that an eosinophil chemotactic factor could be identical with LTB4 was not verified.

A novel leukotriene produced by stimulation of leukocytes with formylmethionylleucylphenylalanine.

Stimulation of human polymorphonuclear leukocytes with the chemotactic peptide formylmethionylleucylphenylalanine led to the formation of a novel leukotriene: 5(S),12(R)-dihydroxy-6,8,10,14-eicosatetraen-1,20-dioic acid. This dihydroxydicarboxylic acid is derived from omega-oxidation of 5(S),12(R),dihydroxy-6,8,10,14-eicosatetradienoic acid (leukotriene B4). The intermediate 5(S),12(R),20-trihydroxy-6,8,10,14-eicosatetraenoic acid was also isolated from these incubations. The two metabolites of leukotriene B4 exhibit chemotactic properties for human polymorphonuclear leukocytes but are less active in this respect than the parent compound.